What does medical affairs earn in DACH pharma 2026?
Medical affairs in DACH pays from junior MSL (€75,000–90,000) to global medical lead (€220,000–300,000). MSL is the frontline role (KOL relationships, scientific presentations); medical advisor and medical manager work at HQ on strategy, evidence generation, plain language summary, publications. Most roles require a doctoral degree (pharmacy, medicine, life sciences) or a master's with significant indication experience. Specialty care (oncology, haematology, rare disease) pays a 15–25% premium.
What medical affairs in pharma actually does
Medical affairs (MA) is the scientific bridge between R&D, commercial, and the external medical community. Medical Science Liaisons (MSLs) build relationships with key opinion leaders (KOLs), present clinical evidence, gather real-world insights, organise advisory boards, and support sales teams with scientific depth. Medical advisors and medical managers at HQ own therapy-area strategy, evidence generation plans, publication planning, investigator-initiated studies (IIS), compassionate use programmes, and medical information. Medical directors lead country or therapy-area teams and sit on the cross-functional leadership team (with commercial, market access, regulatory).
Who hires medical affairs in DACH
Big Pharma DACH affiliates run structured MA teams with 50–150 MSLs per DACH region and 20–60 HQ medical roles: Bayer, Roche, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, GSK, Merck KGaA, Sanofi, Janssen, Lilly, MSD, BMS, AbbVie. Specialty pharma (oncology, rare disease, haematology): BioNTech, Daiichi Sankyo, Vertex, BioMarin, Alnylam, Ipsen, Servier, Otsuka, Incyte, Jazz, Amgen, Recordati. Diagnostics and medical devices with clinical advisory: Roche Diagnostics, Abbott, BD. CSOs (Ashfield Health, Trinity, Innovex) offer contract MSL roles for launch projects. Locations: Munich, Berlin, Basel, Vienna, Frankfurt, Darmstadt.
Medical affairs salary bands DACH 2026
Junior MSL (0–2 years) €75,000–90,000, MSL (2–5 years) €90,000–115,000, senior MSL €115,000–140,000. Therapy area MSL lead €140,000–165,000. Medical advisor HQ €110,000–140,000, senior medical advisor €140,000–170,000. Medical manager / medical lead €165,000–200,000. Medical director country €195,000–240,000. Global medical lead (one molecule) €200,000–260,000. Therapy area head €220,000–280,000. Specialty care (oncology, haematology, rare disease) pays a 15–25% premium. A doctoral degree (Dr. med., Dr. pharm., PhD) is a prerequisite at 80%+ of senior roles. Bonus 15–25%, company car or mobility budget standard.
The hidden medical affairs job market
MSL roles are 50–60% visible (LinkedIn Jobs, MSL Society Job Board, pharma career portals). HQ medical advisor roles are 60–70% hidden — specialist headhunters (Hays Life Sciences Medical, Real Staffing Medical, ProClinical Medical Affairs, Robert Half Pharma) and direct outreach by in-house TA. Medical manager, medical director, and therapy area head are 80–90% hidden — Egon Zehnder, Russell Reynolds, Heidrick & Struggles, Spencer Stuart for senior executive search. Specialty care indications (oncology, haematology, ATMP, rare disease) have the highest hidden share.
Medical affairs career paths in DACH
MSL track: junior MSL (1–2 years) → MSL (3–5 years) → senior MSL (2–3 years) → therapy area MSL lead or HQ move as medical advisor. HQ track: medical advisor (2–3 years) → senior medical advisor (3–4 years) → medical manager (3–5 years) → medical director country → global medical lead or therapy area head. Cross-functional paths: move from MSL into market access or commercial with strategic interest; from medical director into country general manager with P&L ambition. My Reverse Recruitment helps plan MSL-to-HQ moves or specialty pivots.
Frequently asked questions
Do I need a doctoral degree for medical affairs in DACH?
For junior MSL and medical advisor in primary care, a master's in pharmacy, medicine, or life sciences with significant indication experience is often sufficient. For senior MSL, medical manager, and all roles in specialty care (oncology, haematology, rare disease), Dr. med., Dr. pharm. or PhD is a prerequisite at 80%+ of roles. At specialty biotech and in oncology, a doctoral degree is practically mandatory.
How do I move from pharmacy or clinic into medical affairs?
From pharmacy (hospital or clinical pharmacy): direct entry as junior MSL is possible, especially in oncology, haematology, and ATMP. From clinic (resident, senior physician, clinical pharmacology): direct entry as medical advisor or MSL in specialty care — indication expertise is the decisive lever. CSO contract MSL roles (Ashfield, Trinity) are common entry paths.
Which therapy areas pay best in medical affairs 2026?
Oncology (especially solid tumour, haematology), rare disease, and ATMP (gene therapy, cell therapy) pay a 15–25% premium over primary care. Senior MSL in oncology €130,000–160,000, medical director oncology €220,000–270,000. Neurology, immunology, and the cardiology renaissance (PCSK9, Lp(a) targeting) also pay a premium over primary care.